| Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes MK Mahapatra, M Karuppasamy, BM Sahoo Reviews in Endocrine and Metabolic Disorders 23 (3), 521-539, 2022 | 86 | 2022 |
| Development of selective and reversible pyrazoline based MAO-A inhibitors: Synthesis, biological evaluation and docking studies M Karuppasamy, M Mahapatra, S Yabanoglu, G Ucar, BN Sinha, A Basu, ... Bioorganic & medicinal chemistry 18 (5), 1875-1881, 2010 | 67 | 2010 |
| Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: A narrative review MK Mahapatra, M Karuppasamy, BM Sahoo Pharmaceutical Research 39 (6), 1233-1248, 2022 | 57 | 2022 |
| Evaluation of wound healing and antimicrobial potentials of Ixora coccinea root extract N Selvaraj, B Lakshmanan, PM Mazumder, M Karuppasamy, SS Jena, ... Asian Pacific Journal of Tropical Medicine 4 (12), 959-963, 2011 | 47 | 2011 |
| Novel dual-targeting anti-proliferative dihydrotriazine-chalcone derivatives display suppression of cancer cell invasion and inflammation by inhibiting the NF-κB signaling pathway FF Gan, R Zhang, HL Ng, M Karuppasamy, W Seah, WH Yeap, SM Ong, ... Food and chemical toxicology 116, 238-248, 2018 | 34 | 2018 |
| Fundamental considerations in drug design MK Mahapatra, M Karuppasamy Computer Aided Drug Design (CADD): From Ligand-Based Methods to Structure …, 2022 | 25 | 2022 |
| Ribisins and Certain Analogues Exert Neuroprotective Effects through Activation of the Keap1‐Nrf2‐ARE Pathway SH Tan, M Karuppasamy, P Lan, Y Zhang, J Hu, X Lai, B Siok‐Cheng Lim, ... ChemMedChem 17 (18), e202200292, 2022 | 4 | 2022 |
| DOCK3 regulates normal skeletal muscle regeneration and glucose metabolism A Samani, M Karuppasamy, KG English, CA Siler, Y Wang, JJ Widrick, ... bioRxiv, 2023 | 2 | 2023 |
| Standardization of zebrafish drug testing parameters for muscle diseases M Karuppasamy, KG English, CA Henry, MC Manzini, JM Parant, ... Disease Models & Mechanisms 17 (1), 2024 | | 2024 |
| P189 Dock7 is an essential driver of skeletal muscle health and function K English, A Samani, K Becker, M Karupassamy, M Alexander Neuromuscular Disorders 33, S112-S113, 2023 | | 2023 |
| P59 Generation and characterization of a novel XMEA mouse model and pharmacological evaluation of autophagy antagonists M Karuppasamy, K English, V Sanders, M Lopez, G Kaur, L Worthey, ... Neuromuscular Disorders 33, S73, 2023 | | 2023 |
| Restoration of brain dystrophin using tricyclo-DNA ASOs restores neurobehavioral deficits in DMD mice M Karuppasamy, MS Alexander Molecular Therapy-Nucleic Acids 32, 841-842, 2023 | | 2023 |
| Acknowledgment to the Reviewers of Journal of Developmental Biology in 2022 E Akat, P Ha, ECP Ambrósio, C Henry, R Andrade, H Hong, J Ball, M Horb, ... | | 2023 |
| Exploration of Keap1-Nrf2-ARE Signaling Pathway Modulators as Potential Neuroprotectants M Karuppasamy PQDT-Global, 2018 | | 2018 |
| Biological Characterization of the Anti-Tumor Properties of Novel Dual-Target Inhibitors of Dihydrofolate Reductase and Thioredoxin Reductase EH Chew, HL Ng, M Kjellander, M Karuppasamy, ASY Chong, WK Chui, ... Free Radical Biology and Medicine 100, S119-S120, 2016 | | 2016 |
| Exploration of the Antioxidant and Nrf2 Inducing Properties of a Group of Small Molecule Compounds That Mimic Peptide Inhibitors of Keap1-Nrf2 Interaction EH Chew, M Karuppasamy, Y Li, MY Lim, TA Vu, X Lai, H Bertrand, ... Free Radical Biology and Medicine 1 (87), S88, 2015 | | 2015 |
| DOCK3 IS ESSENTIAL FOR NORMAL MUSCLE REGENERATION AND GLUCOSE METABOLISM A SAMANI, Y WANG, KG ENGLISH, M KARUPPASAMY, JJ WIDRICK The Role of DOCK3 In Normal Skeletal Muscle Function and Metabolism, 96, 0 | | |
| How can India influence drug discovery and development KS Rao, P Jayaram, M Karuppasamy | | |
Dr. Biswa Mohan SahooProfessor,School of Pharmacy and Life Sciences, Centurion University of Technology & Management,BBSR在 cutm.ac.in 的电子邮件经过验证
